Ligand Pharmaceuticals Incorporated (LGND) News
Filter LGND News Items
LGND News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LGND News Highlights
- LGND's 30 day story count now stands at 7.
- Over the past 21 days, the trend for LGND's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about LGND are DEC and MBC.
Latest LGND News From Around the Web
Below are the latest news stories about LIGAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LGND as an investment opportunity.
13 Most Promising Small-Cap Stocks According to AnalystsIn this piece, we will take a look at the 13 most promising small-cap stocks according to analysts. If you want to skip our overview of small cap investing and the latest stock market news, then you can take a look at the 5 Most Promising Small-Cap Stocks To Buy. Within the broader world of […] |
Ligand Pharmaceuticals (LGND) Just Overtook the 200-Day Moving AverageGood things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react? |
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio ProgressLigand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years. |
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 GuidanceSAN DIEGO, December 12, 2023--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance. A copy of the presentation and a replay of the webcast are available at investor.ligand. |
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 MutationsThree posters examining ELAINE clinical trials were presented last week at SABCSCOLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the three poster presentations examining clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies. The presentations were |
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York CitySAN DIEGO, December 06, 2023--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. |
Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsPalvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with Microcystic Lymphatic Malformations U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ rapamycin for the Treatment of Microcystic Lymphatic Malformations in November 2023 WAYNE, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company |
Tharimmune (THAR) Up on Positive Data From Pipeline CandidateTharimmune (THAR) announces positive data from a phase I study on TH104 and the development timeline in chronic pruritis in primary biliary cholangitis indication. |